Biogen Launches Lucentis Biosimilar Byooviz In Canada
As Natco Introduces First Pomalyst Generic Approved By Health Canada
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
